Strategies Targeting CAMP Signaling in the Treatment of Polycystic Kidney Disease

Overview

Journal J Am Soc Nephrol

Specialty Nephrology

Date 2013 Dec 17

PMID 24335972

Citations 143

Authors

Vicente E Torres

Peter C Harris

Affiliations

Soon will be listed here.

Abstract

Polycystic kidney disease (PKD) is a leading cause of ESRD worldwide. In PKD, excessive cell proliferation and fluid secretion, pathogenic interactions of mutated epithelial cells with an abnormal extracellular matrix and alternatively activated interstitial macrophages, and the disruption of mechanisms controlling tubular diameter contribute to cyst formation. Studies with animal models suggest that several diverse pathophysiologic mechanisms, including dysregulation of intracellular calcium levels and cAMP signaling, mediate these cystogenic mechanisms. This article reviews the evidence implicating calcium and cAMP as central players in a network of signaling pathways underlying the pathogenesis of PKD and considers the therapeutic relevance of treatment strategies targeting cAMP signaling.

Citing Articles

A Rare Coexisting Presentation of Autosomal Dominant Polycystic Kidney Disease With Rapid Deterioration of Renal Function and Neurofibromatosis Type 1.

Noishiki H, Yamauchi H, Komaki K, Kusaba T, Tamagaki K Cureus. 2025; 17(3):e79931.

PMID: 40051696 PMC: 11883721. DOI: 10.7759/cureus.79931.

Commentary: Tolvaptan for Autosomal Dominant Polycystic Kidney Disease (ADPKD) - an update.

Gittus M, Haley H, Harris T, Borrows S, Padmanabhan N, Gale D BMC Nephrol. 2025; 26(1):79.

PMID: 39953521 PMC: 11827152. DOI: 10.1186/s12882-025-03960-4.

Targeting TRPM3 as a potential therapeutic approach for autosomal dominant polycystic kidney disease.

Gul H, Davies J Sci Rep. 2025; 15(1):4714.

PMID: 39922884 PMC: 11807189. DOI: 10.1038/s41598-025-89200-z.

Scalable production of uniform and mature organoids in a 3D geometrically-engineered permeable membrane.

Kim D, Lim H, Youn J, Park T, Kim D Nat Commun. 2024; 15(1):9420.

PMID: 39482314 PMC: 11528013. DOI: 10.1038/s41467-024-53073-z.

MicroRNA and renal fibrosis in autosomal dominant polycystic kidney disease: a longitudinal study.

Lai S, Mastroluca D, Perrotta A, Muscaritoli M, Lucciola S, Felli M J Nephrol. 2024; 38(1):153-162.

PMID: 38969871 PMC: 11903767. DOI: 10.1007/s40620-024-01965-0.

References

Chun K, Lao H, Langenbach R . The prostaglandin E2 receptor, EP2, stimulates keratinocyte proliferation in mouse skin by G protein-dependent and {beta}-arrestin1-dependent signaling pathways. J Biol Chem. 2010; 285(51):39672-81. PMC: 3000948. DOI: 10.1074/jbc.M110.117689. View

Qian F, Germino F, Cai Y, Zhang X, Somlo S, Germino G . PKD1 interacts with PKD2 through a probable coiled-coil domain. Nat Genet. 1997; 16(2):179-83. DOI: 10.1038/ng0697-179. View

Howe A . Regulation of actin-based cell migration by cAMP/PKA. Biochim Biophys Acta. 2004; 1692(2-3):159-74. DOI: 10.1016/j.bbamcr.2004.03.005. View

Joly D, Morel V, Hummel A, Ruello A, Nusbaum P, Patey N . Beta4 integrin and laminin 5 are aberrantly expressed in polycystic kidney disease: role in increased cell adhesion and migration. Am J Pathol. 2003; 163(5):1791-800. PMC: 1892423. DOI: 10.1016/s0002-9440(10)63539-0. View

Meijer E, Gansevoort R, de Jong P, van der Wal A, Leonhard W, de Krey S . Therapeutic potential of vasopressin V2 receptor antagonist in a mouse model for autosomal dominant polycystic kidney disease: optimal timing and dosing of the drug. Nephrol Dial Transplant. 2011; 26(8):2445-53. DOI: 10.1093/ndt/gfr069. View

Tsiokas L, Arnould T, Zhu C, Kim E, Walz G, Sukhatme V . Specific association of the gene product of PKD2 with the TRPC1 channel. Proc Natl Acad Sci U S A. 1999; 96(7):3934-9. PMC: 22398. DOI: 10.1073/pnas.96.7.3934. View

Witzgall R . Polycystin-2--an intracellular or plasma membrane channel?. Naunyn Schmiedebergs Arch Pharmacol. 2005; 371(4):342-7. DOI: 10.1007/s00210-005-1027-9. View

Hogan M, Manganelli L, Woollard J, Masyuk A, Masyuk T, Tammachote R . Characterization of PKD protein-positive exosome-like vesicles. J Am Soc Nephrol. 2009; 20(2):278-88. PMC: 2637052. DOI: 10.1681/ASN.2008060564. View

Li M, Wang X, Meintzer M, Laessig T, Birnbaum M, Heidenreich K . Cyclic AMP promotes neuronal survival by phosphorylation of glycogen synthase kinase 3beta. Mol Cell Biol. 2000; 20(24):9356-63. PMC: 102192. DOI: 10.1128/MCB.20.24.9356-9363.2000. View

10.

Wang C, Creed C, Winklhofer F, Grantham J . Water prescription in autosomal dominant polycystic kidney disease: a pilot study. Clin J Am Soc Nephrol. 2010; 6(1):192-7. PMC: 3022242. DOI: 10.2215/CJN.03950510. View

11.

Boletta A, Qian F, Onuchic L, Bragonzi A, Cortese M, Deen P . Biochemical characterization of bona fide polycystin-1 in vitro and in vivo. Am J Kidney Dis. 2001; 38(6):1421-9. DOI: 10.1053/ajkd.2001.29282. View

12.

Eid A . cAMP induces adhesion of microvascular smooth muscle cells to fibronectin via an Epac-mediated but PKA-independent mechanism. Cell Physiol Biochem. 2012; 30(1):247-58. DOI: 10.1159/000339061. View

13.

Ostrom L, Tang M, Gruss P, Dressler G . Reduced Pax2 gene dosage increases apoptosis and slows the progression of renal cystic disease. Dev Biol. 2000; 219(2):250-8. DOI: 10.1006/dbio.2000.9618. View

14.

Nadasdy T, Lajoie G, Laszik Z, Blick K, Silva F . Cell proliferation in the developing human kidney. Pediatr Dev Pathol. 1999; 1(1):49-55. DOI: 10.1007/s100249900006. View

15.

Pringle D, Yin Z, Lee A, Manchanda P, Yu L, Parlow A . Thyroid-specific ablation of the Carney complex gene, PRKAR1A, results in hyperthyroidism and follicular thyroid cancer. Endocr Relat Cancer. 2012; 19(3):435-46. PMC: 3667702. DOI: 10.1530/ERC-11-0306. View

16.

Starremans P, Li X, Finnerty P, Guo L, Takakura A, Neilson E . A mouse model for polycystic kidney disease through a somatic in-frame deletion in the 5' end of Pkd1. Kidney Int. 2008; 73(12):1394-405. DOI: 10.1038/ki.2008.111. View

17.

Mutig K, Paliege A, Kahl T, Jons T, Muller-Esterl W, Bachmann S . Vasopressin V2 receptor expression along rat, mouse, and human renal epithelia with focus on TAL. Am J Physiol Renal Physiol. 2007; 293(4):F1166-77. DOI: 10.1152/ajprenal.00196.2007. View

18.

Nauli S, Alenghat F, Luo Y, Williams E, Vassilev P, Li X . Polycystins 1 and 2 mediate mechanosensation in the primary cilium of kidney cells. Nat Genet. 2003; 33(2):129-37. DOI: 10.1038/ng1076. View

19.

Morel N, Vandenberg G, Ahrabi A, Caron N, Desjardins F, Balligand J . PKD1 haploinsufficiency is associated with altered vascular reactivity and abnormal calcium signaling in the mouse aorta. Pflugers Arch. 2008; 457(4):845-56. DOI: 10.1007/s00424-008-0561-y. View

20.

GARDNER Jr K, REED W, Evan A, Zedalis J, Hylarides M, Leon A . Endotoxin provocation of experimental renal cystic disease. Kidney Int. 1987; 32(3):329-34. DOI: 10.1038/ki.1987.213. View